Moderna Inc.

November 4, 2022

Study finds Moderna’s COVID-19 vaccine safe and effective for young children

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

By Bill Snyder
June 16, 2022

VUMC research aids approval of COVID-19 vaccine for young children

The U.S. Food and Drug Administration is expected to authorize Pfizer and Moderna’s COVID-19 vaccines for children as young as 6 months old as early as tomorrow, following the unanimous recommendation by an FDA advisory panel on Wednesday.

By Bill Snyder
May 12, 2022

VUMC-led study finds Moderna COVID vaccine safe and effective for children

By Bill Snyder
April 13, 2022

Volunteering for vaccine research a family affair

By Kristin Smart
January 24, 2022

Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines

Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.

By Jessica Pasley
November 23, 2021

VUMC researchers involved in developing Moderna’s COVID-19 vaccine featured in Smithsonian exhibit

Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.

By Bill Snyder
March 30, 2021

Monroe Carell Jr. Children’s Hospital at Vanderbilt selected as trial site for pediatric COVID-19 vaccine

Monroe Carell Jr. Children’s Hospital at Vanderbilt is set to begin a phase 2/3 clinical trial to study the safety and efficacy of the Moderna COVID-19 vaccine in children.
By Christina Echegaray
September 17, 2020

HHS Secretary Azar visits VUMC

U.S. Health and Human Services Secretary Alex Azar visited VUMC Tuesday, Sept. 15, to learn more about the Medical Center’s ongoing Moderna COVID-19 vaccine trial and the convalescent plasma trial.
By VUMC News and Communications
July 15, 2020

Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
By Bill Snyder
July 14, 2020

VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
By Leigh MacMillan
September 13, 2019

Early effort to thwart chikungunya infection shows positive results

Phase 1 trial results in new approach to combat the chikungunya
By Bill Snyder
June 14, 2019

New method tested to block chikungunya infection

Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
By Bill Snyder
February 21, 2019

VUMC chikungunya antibody set to enter clinical trial

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
By Bill Snyder
1 2